While Akiso's Harmony 6 trial in China showed a survival benefit for its PD-1/VEGF bispecific with chemotherapy, it doesn't resolve the key question of whether these impressive results from Chinese populations will translate to a global patient population.

With half its patients from Asia and only 13% from North America, the Destiny Breast 11 trial's results may not be fully generalizable to US patients. Differences in metabolism, healthcare systems, and side effect reporting across regions can impact outcomes, a key consideration when interpreting global trial data.

Despite strong efficacy data, the drug DV-Toripalimab scored lower than a competitor (2.5 vs 3.0). Experts attribute this confidence gap to its Phase 3 trial being conducted only in China, which raises generalizability concerns and reflects a lack of hands-on experience for Western physicians.

Despite statistically significant results, Akiso's successful China-only study faced skepticism due to its trial design. Exclusions of older patients and those with high bleeding risk cast doubt on whether the positive findings can be replicated in a diverse global population, posing a barrier to wider acceptance.

By enrolling more participants, Chinese clinical trials achieve greater statistical power. This reduces the likelihood of both Type 1 (false positive) and Type 2 (false negative) errors, leading to more reliable data and a lower chance of abandoning a truly effective drug.

The phase 3 trial for luspatercept narrowly missed its primary endpoint because of an unusually high placebo response in the Asia-Pacific region, especially China. After a single patient's data was re-adjudicated, the p-value became significant, highlighting how operational factors and regional practices can mask a drug's true efficacy in global trials.

The debate over Summit's Ivanecimab lung cancer data from its China-based Harmony 6 trial shows the risk of assuming data is globally applicable. Differences in patient populations, such as smoking history in squamous cell carcinoma, can make clinical results from one region non-translatable to another, posing a major challenge for global drug developers.

The STARGLO trial (glofitamab-gemox) showed a strong survival benefit in Asia-Pacific patients but not in the small North American cohort. This geographic discrepancy, with only 9% of patients from the US, was a key reason the FDA did not approve the combination, while European agencies did.

The INDEPENDENCE trial's initial results were confounded by external factors in specific regions. In Mainland China, restricted transfusion practices and a blood shortage led to a 40% placebo response rate, significantly higher than the drug's response rate in that region. This demonstrates how logistical and healthcare system realities can be critical confounding variables in global clinical studies.